Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

Researchers identified how a brain circuit involving dopamine and GLP-1 receptor impact palatability and hedonic eating.

Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Chinese companies are involved in one-fifth of pharma’s clinical development programs, but trade wars and regulatory hurdles ...

Terns’ pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR ...

While furosemide and other diuretics can help with symptoms, the drugs that have had a very significant impact on the ...

Terns Pharmaceuticals, Inc.’s TERN share price has surged by 14.97%, which has investors questioning if this is right time to ...

(MENAFN- GlobeNewsWire - Nasdaq) Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small ... agonist lead compounds, including single- and multi-acting GLP-1, GIP, or glucagon ...

small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist for obesity The FALCON Phase 2 clinical trial enrolled its first patient in March 2025, with 12-week data expected in the fourth quarter ...